Penumbra
Builds clot-removal, embolization, and vascular-access devices for neurovascular and peripheral procedures.
Something off on this page? Send us feedback.
Profile
Sells thrombectomy systems plus embolization and vascular-access devices to specialist physicians. Computer-assisted vacuum thrombectomy connects products used across stroke, pulmonary, venous, and peripheral arterial procedures, while the business operates as one segment and depends on regulatory clearance, manufacturing controls, and safe performance in acute care.
Develops, manufactures, and markets devices for removing blood clots and treating neurovascular and peripheral vascular disease. The single operating segment is organized around thrombectomy products and embolization and access products, with computer-assisted vacuum thrombectomy spanning stroke, pulmonary, venous, and peripheral arterial procedures.
Built through in-house engineering, testing, clinical, regulatory, and commercial capabilities, the portfolio grew from neurovascular access into a head-to-toe thrombectomy platform. Direct sales teams were established early in the United States and Europe, while specialist-physician relationships guide product development and adoption.
Product performance depends on regulatory clearance, manufacturing controls, and safe use in acute procedures. The JET 7 Xtra Flex catheter underwent a Class I recall, later terminated, and the agreed acquisition by Boston Scientific remains pending after shareholder approval.
Company facts
Categories
Key statistics
Year to date +4.0% · Average volume (30d) 314.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI | Reiterate | Outperform | $335 | $320 | |
| May 7, 2026 | Evercore ISI | Target | $360 | $335 | ||
| Feb 26, 2026 | UBS | Target | $335 | $374 | ||
| Feb 25, 2026 | Evercore ISI | Target | $340 | $360 | ||
| Jan 20, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform | $355 | $374 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.16 | $0.88 | −24.1% | $389.6M | $390.0M | +0.1% | +0.43% |
| May 6, 2026Q1 FY26 | $1.06 | $0.82 | −22.6% | $370.5M | $374.8M | +1.2% | +0.14% |
| Feb 25, 2026Q4 FY25 | $1.11 | $1.18 | +6.3% | $361.9M | $385.4M | +6.5% | +0.97% |
| Nov 5, 2025Q3 FY25 | $0.93 | $0.97 | +4.4% | $341.0M | $354.7M | +4.0% | +17.32% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $324.1M | $339.5M | $354.7M | $385.4M | $374.8M | $390.0M | |
| Gross profit | $215.9M | $224.0M | $240.4M | $262.1M | $253.4M | $264.9M | |
| Operating income | $40.4M | $40.8M | $48.8M | $59.2M | $38.2M | $41.0M | |
| Net income | $39.2M | $45.3M | $45.9M | $47.3M | $32.6M | $34.8M | |
| Diluted EPS | $1.00 | $1.15 | $1.17 | $1.20 | $0.82 | $0.88 | |
| Gross margin | 66.6% | 66.0% | 67.8% | 68.0% | 67.6% | 67.9% | |
| Operating margin | 12.4% | 12.0% | 13.8% | 15.4% | 10.2% | 10.5% |
Fiscal years (4-quarter sums)FY21 $747.6M · FY22 $847.1M · FY23 $1.06B · FY24 $1.19B · FY25 $1.40B
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $658.8M · Total debt $212.7M · Total assets $1.97B · Shareholders' equity $1.53B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 39.39M · Float 38.29M · 97.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.30M | 10.91% | 13F | Aug 7, 2026 |
| Barclays PLC | 2.34M | 5.95% | 13G | Aug 13, 2026 |
| HBK Investments L P | 1.84M | 4.67% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.71M | 4.34% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 1.67M | 4.23% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 2, 2026 | Harpreet Grewal | director | −100 | $328.22 |
| Mar 2, 2026 | Maggie Yuen | officer: Chief Financial Officer | −2,432 | $342.30 |
| Jan 6, 2026 | Harpreet Grewal | director | −186 | $312.64 |
| Jan 2, 2026 | Thomas Wilder | director | −186 | $310.72 |
| Dec 11, 2025 | Arani Bose | director | −15,000 | $308.82 |
Peers
- Stryker
Broad overlap in stroke and peripheral mechanical thrombectomy
- Medtronic
Direct overlap in stroke thrombectomy, embolization, and access
- Boston Scientific
Peripheral thrombectomy, thrombolysis, and embolization overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Penumbra | $321.68 | −0.05% | $12.67B | 79.0 | 58.1 | 8.4 | +14.9% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 24.5 | 15.3 | 3.3 | +9.4% |